How Much Do You Really Need Invested in Bristol Myers Squibb to Collect $10,000 a Year?

How Much Do You Really Need Invested in Bristol Myers Squibb to Collect $10,000 a Year?

Chris Lange

Sat, September 12, 2026 at 10:15 PM GMT+3 5 min read

• BMY -0.17%

Quick Read

• Collecting $10,000 annually from BMY requires roughly 3,968 shares and about $252,000 in capital at its current 3.94% yield.

• Eliquis faces a revenue step-down of between $1.5 billion and $2 billion in 2027 along with U.S. patent expiration in April 2028, threatening the earnings that fund BMY's dividend.

• BMY's Growth Portfolio now drives nearly 60% of revenue and grew 14%, while the stock has surged over 40% in the past year.

• Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Bristol Myers Squibb didn't make the cut. Enter your email to see the names that beat BMY. The report is free. Enter your email and see if any of your stocks made the cut.

The exercise is simple: how large a position in Bristol Myers Squibb (NYSE:BMY) do you need to throw off $10,000 a year in dividend income? Start with the income target and solve backward, using the live yield and the live payout. That is the only way the number means anything.

Bristol Myers Squibb is a global biopharmaceutical company that develops and sells prescription medicines across oncology, hematology, immunology and cardiovascular disease, with headline franchises including Eliquis, Opdivo, Reblozyl, Camzyos, Breyanzi, Opdualag and Cobenfy. It is a large-cap pharma with a market capitalization of roughly $130.0 billion and $49.19 billion in trailing revenue.

Live Math on BMY

The dividend inputs, straight off the tape:

• Forward annual dividend: $2.52 per share, paid as a $0.63 quarterly.

• Share price: $63.62 as of September 11, 2026.

• Dividend yield: 3.94%.

The share count needed for $10,000 in annual income equals the target divided by the per-share dividend ($10,000 / $2.52). The capital required equals that share count multiplied by the current price ($63.62). At the current 3.94% yield, the capital figure lands near a quarter of a million dollars, and the share count sits just under four thousand. Plug in the live quote before you size anything, because both variables move.

Free Report, Just Released

Why Didn't BMY Make The Top 10 List?

24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now. Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now.

And BMY didn't make the cut!

The report is free, and you can see why we think each stock is a top investment today.

Enter Your Email and See the Ten →

What This Snapshot Does and Does Not Tell You

The capital figure is a photograph at today's price and today's payout. It changes when either changes. Buy at a lower price and you need less money to reach $10,000. Buy at a higher price and you need more. A dividend increase lowers the bar over time. A cut raises it. BMY's dividend history is one of the longer streaks in large-cap pharma: 17 consecutive annual increases and 94 consecutive years of dividend payments, with the most recent hike a 1.6% bump alongside the Q4 2025 earnings report.

Risk Income Articles Skip: Patent Cliffs

Ten thousand dollars a year from one pharmaceutical company is a large position facing one set of risks. The dominant one is structural. Pharmaceutical revenue runs on patents, and patents expire. When exclusivity ends on a major drug, generic and biosimilar competition can take a large share of that revenue in a hurry.

For BMY, the specific number to internalize is Eliquis, the company's largest product at $4.14 billion in Q1 2026 revenue, up 16% year over year. Management still expects a $1.5 to $2 billion revenue step-down in 2027 tied to Eliquis pricing and European loss of exclusivity, with U.S. loss of exclusivity landing in April 2028. The Legacy Portfolio (Revlimid, Pomalyst, Sprycel, Abraxane) is already declining 12 to 16% on generic pressure. If the pipeline does not backfill on time, the earnings power that funds the payout narrows.

Balance Sheet Muscle and Growth Portfolio Momentum

BMY has real financial firepower. Management pointed to roughly $11.5 billion in cash and marketable securities at the end of Q2, $3.4 billion in quarterly operating cash flow, and $1.2 billion of additional debt paydown in the same quarter. The Growth Portfolio (Opdivo, Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy) is now nearly 60% of total revenue and grew 14%. Management has flagged the potential for more than 10 new medicines by the end of the decade plus over 30 lifecycle management opportunities. The stock has also rerated: shares are up 40.25% over the past year and 21.94% year-to-date, with a forward P/E of 10.

What to Watch on the Income

1. Pull the live yield and price before sizing. At $2.52 per share, a $63.62 price implies a very different share count than a $50 or $75 print.

2. Track free cash flow coverage of the dividend each quarter. The commitment is only as durable as the cash generating it.

3. Watch pipeline readouts that determine whether Eliquis revenue gets replaced, including Milvexian's atrial fibrillation readout in Q1 2027, the mesignamide PDUFA on May 13, 2027, and Cobenfy ADEPT readouts starting early 2027.

The math is easy. The risk is the patent cliff. Size the position around both.

Got $1,000? Before You Buy BMY, Read This

If you have cash sitting in your account right now, give this two minutes. After more than two decades of helping investors beat the market, our top analysts at 24/7 Wall St. put together a definitive report on the Top 10 Stocks To Buy Today. And BMY wasn't one of them.

They combed the entire market. It's not 10 ideas, not 10 stocks everyone is talking about, it's what their research points to as the 10 best stocks to buy right now, and it's free. Read more here and see which stocks made the list -->>

Contact editorial@247wallst.com for any questions or corrections.